Tacrolimus (FK506) proves superior to OKT3 for treating episodes of persistent rejection following intrathoracic transplantation.
Meiser
B M
BM
Department of Cardiac Surgery, University of Munich, Grosshadern Medical Center, Germany.
Uberfuhr
P
P
Schulze
C
C
Fuchs
A
A
Mair
H
H
Reichenspurner
H
H
Kreuzer
E
E
Reichart
B
B
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy*; D016027:Heart Transplantation / Q000276:immunology* / Q000379:methods; D016041:Heart-Lung Transplantation / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016040:Lung Transplantation / Q000276:immunology*; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016559:Tacrolimus; D008775:Methylprednisolone; D008727:Methotrexate